Abstract
Immuno-oncology approaches mainly utilize monoclonal antibodies or protein-based scaffolds that bind with high affinity to cancer cells and can generate an immune response. Peptides can also bind with high affinity to cancer cells and are intermediate in size between antibodies and small molecules. They are also synthetically accessible and therefore easily modified to optimize their stability, binding affinity and selectivity. Here we describe the design of immune system engagers (ISErs), a novel class of synthetic peptide-based compounds that bind specifically to cancer cells and stimulate the immune system. A prototype, Y9, targets integrin α 3, which is overexpressed on several cancer cells, and activates the immune system via a formyl methionine-containing effector peptide. Injection of Y9 leads to immune cell infiltration into tissue and prevents tumor formation in a guinea pig model. The anti-Tumor activity and synthetic accessibility of Y9 illustrate that ISErs could be applied to a wide variety of targets and diseases.
Original language | English |
---|---|
Article number | 17592 |
Number of pages | 11 |
Journal | Scientific Reports |
Volume | 7 |
DOIs | |
Publication status | Published - 14 Dec 2017 |
Austrian Fields of Science 2012
- 104004 Chemical biology
Keywords
- FORMYL PEPTIDE RECEPTORS
- MONOCLONAL-ANTIBODIES
- LISTERIA-MONOCYTOGENES
- BISPECIFIC ANTIBODIES
- LEU-PHE
- THERAPY
- MOLECULES
- PROTEINS
- LIGANDS
- IMMUNOTHERAPY